NeoGenomics, Inc. Forecast, price target & analysts
NeoGenomics, Inc. Target price 2025 - Analyst rating & recommendation
NeoGenomics, Inc. Classifications & Recommendation:
NeoGenomics, Inc. Price Target
| Target Price | $18.67 |
| Price | $9.82 |
| Potential |
90.09%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target NeoGenomics, Inc. 2026 .
The average NeoGenomics, Inc. target price is $18.67.
This is
90.09%
register free of charge
$26.00
164.77%
register free of charge
$15.00
52.75%
register free of charge
|
|
| A rating was issued by 15 analysts: 10 Analysts recommend NeoGenomics, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the NeoGenomics, Inc. stock has an average upside potential 2026 of
90.09%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 660.57 | 738.14 |
| 11.65% | 11.74% | |
| EBITDA Margin | 0.13% | 7.55% |
| 103.16% | 5,767.42% | |
| Net Margin | -12.03% | -9.86% |
| 20.67% | 18.02% |
15 Analysts have issued a sales forecast NeoGenomics, Inc. 2025 . The average NeoGenomics, Inc. sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an NeoGenomics, Inc. EBITDA forecast 2025. The average NeoGenomics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 NeoGenomics, Inc. Analysts have issued a net profit forecast 2025. The average NeoGenomics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.62 | -0.57 |
| 11.43% | 8.06% | |
| P/E | negative | |
| EV/Sales | 2.01 |
9 Analysts have issued a NeoGenomics, Inc. forecast for earnings per share. The average NeoGenomics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the NeoGenomics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
NeoGenomics, Inc....
Current NeoGenomics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler | Locked ➜ Locked | Locked | Feb 26 2025 |
| B of A Securities | Locked ➜ Locked | Locked | Feb 19 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 19 2025 |
| Goldman Sachs | Locked ➜ Locked | Locked | Jan 28 2025 |
| Benchmark | Locked ➜ Locked | Locked | Jan 16 2025 |
| Needham | Locked ➜ Locked | Locked | Jan 15 2025 |
| Benchmark | Locked ➜ Locked | Locked | Jan 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
B of A Securities: Locked ➜ Locked
|
Feb 19 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 19 2025 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Jan 28 2025 |
|
Locked
Benchmark: Locked ➜ Locked
|
Jan 16 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Jan 15 2025 |
|
Locked
Benchmark: Locked ➜ Locked
|
Jan 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
